This role owns the medical strategy and execution for a novel Interleukin-33 targeting monoclonal antibody, crafting both product and disease area direction across the full lifecycle
Job Summary
This role owns the medical strategy and execution for a novel Interleukin-33 targeting monoclonal antibody, crafting both product and disease area direction across the full lifecycle.
Lead and grow the COPD US medical team, setting clear vision, priorities and standards for excellence in disease area and brand strategy and execution.
Partner with evidence generation teams to define and execute real-world evidence programs that address US clinical, payer and policy needs.
Matching Summary
This role owns the medical strategy and execution for a novel Interleukin-33 targeting monoclonal antibody, crafting both product and disease area direction across the full lifecycle.